SCHEMBL2018777

SCHEMBL2018777

C[C@@H]1C[C@H]1CNCCc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.51
HRH1 P35367 1/20 0.51
FUCA1 P04066 4/20 0.49
SIGMAR1 Q99720 7/20 0.48
GAA P10253 2/20 0.48
MAPT P10636 1/20 0.48
ATM Q13315 1/20 0.47
TAAR1 Q96RJ0 1/20 0.47
HTR2C P28335 1/20 0.44
KCNH2 Q12809 2/20 0.43
NPC1 O15118 1/20 0.42
KDM1A O60341 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
HTR1A P08908 1/20 0.42
ADRA2A P08913 1/20 0.42
CYP2C8 P10632 1/20 0.42
CYP2D6 P10635 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20858886 0.89 HTR2A (0.43) HTR2AHRH1FUCA1SIGMAR1GAA
SCHEMBL2019717 0.81 HTR2C (0.64) HTR2AFUCA1GAAMAPTHTR2C
SCHEMBL2019718 0.81 HTR2C (0.64) HTR2AFUCA1GAAMAPTHTR2C
Hydrochloric Acid SCHEMBL4523862 0.80 HTR2C (0.62) HTR2AFUCA1GAAMAPTHTR2C
SCHEMBL91436 0.77 BCHE (0.64) SIGMAR1NPC1ALDH1A1LMNACYP1A2
SCHEMBL1967142 0.76 HTR2A (0.56) HTR2AHRH1SIGMAR1GAAMAPT
SCHEMBL18828474 0.75 SLC18A2 (0.47) FUCA1
SCHEMBL283735 0.73 SIGMAR1 (0.81) SIGMAR1GAAMAPTATMTAAR1
SCHEMBL17667739 0.73 EPHX2 (0.58) HTR2AHRH1SIGMAR1GAAMAPT
SCHEMBL273721 0.72 SIGMAR1 (0.74) SIGMAR1GAAMAPTATMTAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8394837-B2 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease Merck, Sharp & Dohme, Corp. (US) 2013-03-12 US disclosed
EP-1817311-B1 2,3,4,6-SUBSTITUTED PYRIDYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME (US) 2012-10-17 EP disclosed
EP-1740581-B1 2, 4, 6-SUBSTITUTED PYRIDYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME (US) 2012-08-22 EP disclosed
US-7968571-B2 2,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's Disease Merck, Sharp & Dohme, Corp. (US) 2011-06-28 US disclosed
US-20080015233-A1 2,4,6-Substituted Pyridyl Derivative Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease MERCK SHARP & DOHME LLC 2008-01-17 US disclosed
US-20070293497-A1 2,3,4,6-Substituted Pyridyl Derivative Compounds Useful As Beta-Secretase Inhibitors For The Treatment Of Alzheimer's Disease MERCK SHARP & DOHME LLC 2007-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293497-A1 2,3,4,6-Substituted Pyridyl Derivative Compounds Useful As Beta-Secretase Inhibitors For The Treatment Of Alzheimer's Disease BACE1, BACE2, PSEN2 HTR2A 1671/4885HRH1 1447/4885FUCA1 1102/4885
US-20080015233-A1 2,4,6-Substituted Pyridyl Derivative Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease BACE1, BACE2, PSEN2 HTR2A 1524/4885HRH1 1664/4885FUCA1 1517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.